Inactive Instrument
NicOx SA Stock Euronext Paris
Stocks
NCOX
FR0000074130
Pharmaceuticals
OTC Markets Traded| Market Cap | 33.93M 39.28M 31.88M 29M 54.52M 3.76B 55.42M 374M 146M 1.88B 147M 144M 6.25B | P/E 2026 * |
-5.5x | P/E 2027 * | 38.5x |
|---|---|---|---|---|---|
| Enterprise Value | 33.93M 39.28M 31.88M 29M 54.52M 3.76B 55.42M 374M 146M 1.88B 147M 144M 6.25B | EV / Sales 2026 * |
11.3x | EV / Sales 2027 * | 3.39x |
| Free-Float |
99.65% | Yield 2026 * |
-
| Yield 2027 * | - |
| 1 day | -7.95% |
| Manager | Title | Age | Since |
|---|---|---|---|
Gavin Spencer
CEO | Chief Executive Officer | 55 | 28/02/2024 |
Sandrine Gestin
DFI | Director of Finance/CFO | 58 | 01/01/2015 |
Doug Hubatsch
CTO | Chief Tech/Sci/R&D Officer | - | 13/12/2021 |
| Director | Title | Age | Since |
|---|---|---|---|
Gavin Spencer
BRD | Director/Board Member | 55 | 08/04/2024 |
Damian Marron
CHM | Chairman | 64 | 16/07/2024 |
Marc Bozec
BRD | Director/Board Member | - | 16/07/2024 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -7.95% | -9.39% | - | - | 39.28M | |
| +0.21% | +5.65% | +61.31% | +24.93% | 335B | |
| +0.04% | -5.02% | +23.07% | -14.92% | 68.61B | |
| -2.00% | -4.33% | +46.66% | +127.90% | 11.2B | |
| -1.47% | -0.82% | -3.44% | -2.46% | 8.49B | |
| -0.34% | +2.22% | -13.22% | -7.03% | 4.84B | |
| +1.45% | +3.85% | -26.84% | +18.44% | 4.42B | |
| +0.32% | -2.16% | +0.82% | +45.84% | 4.28B | |
| +2.57% | +1.51% | +13.28% | +56.25% | 2.81B | |
| -1.59% | -2.84% | -4.94% | -2.50% | 2.19B | |
| Average | -0.88% | -0.65% | +10.75% | +27.39% | 49.11B | |
| Weighted average by Cap. | +0.11% | +3.38% | +50.84% | +20.68% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 3M 3.47M 2.82M 2.56M 4.82M 332M 4.9M 33.03M 12.91M 166M 13.04M 12.76M 553M | 10M 11.58M 9.4M 8.55M 16.07M 1.11B 16.33M 110M 43.05M 554M 43.47M 42.53M 1.84B |
| Net income | -6M -6.95M -5.64M -5.13M -9.64M -664M -9.8M -66.06M -25.83M -333M -26.08M -25.52M -1.11B | 1M 1.16M 940K 855K 1.61M 111M 1.63M 11.01M 4.3M 55.44M 4.35M 4.25M 184M |
| Net Debt | - | - |
Employees
-
Sector
Pharmaceuticals
